Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLK2 | Q86UE8 | 6/20 | 0.60 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.60 |
| ▸ | JAK3 | P52333 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | PIM1 | P11309 | 2/20 | 0.53 |
| ▸ | CDK2 | P24941 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 4/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
| ▸ | NEK2 | P51955 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6409208 | 1.00 | TLK2 (0.60) | TLK2PDPK1JAK3MEN1KMT2A | |
| SCHEMBL6409195 | 0.82 | RET (0.58) | PDPK1PIM1 | |
| SCHEMBL6409193 | 0.82 | RET (0.58) | PDPK1PIM1 | |
| SCHEMBL5843095 | 0.81 | PDPK1 (0.47) | PDPK1JAK3RAF1 | |
| SCHEMBL5843099 | 0.81 | PDPK1 (0.47) | PDPK1JAK3RAF1 | |
| SCHEMBL5473025 | 0.81 | PDGFRB (0.57) | TLK2PDPK1JAK3MEN1KMT2A | |
| SCHEMBL5473028 | 0.81 | PDGFRB (0.57) | TLK2PDPK1JAK3MEN1KMT2A | |
| SCHEMBL5182063 | 0.79 | PDPK1 (0.60) | PDPK1CDK2KDRPDGFRBFGFR1 | |
| SCHEMBL5182059 | 0.79 | PDPK1 (0.60) | PDPK1CDK2KDRPDGFRBFGFR1 | |
| SCHEMBL5430411 | 0.76 | CDK2 (0.52) | PDPK1CDK2KDRPDGFRBFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855730-B2 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | disclosed |
| US-6531502-B1 | Antitumor | SUGEN, INC. | 2003-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | DMPK, MAP4K3, MAP3K20 | TLK2 413/4885PDPK1 45/4885JAK3 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.